Skip to main content

Prostate cancer

15-02-2019 | Prostate cancer | News | Article

Further support for [177Lu]-PSMA-617 in men with mCRPC

Results from an expansion cohort add support for the use of lutetium-177-prostate-specific membrane antigen-617 in heavily pretreated men with metastatic castration-resistant prostate cancer.

15-02-2019 | Prostate cancer | News | Article

Real-world data confirm better mCRPC OS with hormonal therapy in Black versus White men

An analysis of a US database shows that Black individuals who receive abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer have better overall survival than their White counterparts.

14-02-2019 | Prostate cancer | News | Article

Long-term data support SBRT for low-, intermediate-risk prostate cancer

Stereotactic body radiotherapy has a favorable long-term disease control and safety profile in the setting of low- or intermediate-risk prostate cancer, say US researchers who analyzed individual patient data from over 2000 prospectively treated men.

12-02-2019 | Prostate cancer | News | Article

Conservative management of low-risk prostate cancer increasing in USA

US patients with low-risk localized prostate cancer are increasingly being managed with active surveillance or watchful waiting, finds a database analysis.

07-02-2019 | Prostate cancer | News | Article

Adding docetaxel to ADT for high-risk nonmetastatic prostate cancer questioned

Supplementing androgen deprivation therapy with docetaxel does not appear to improve the outcomes of men with high-risk nonmetastatic prostate cancer and rising prostate-specific antigen levels after treatment, indicate phase III trial findings.

04-02-2019 | Prostate cancer | News | Article

Time to prostate cancer surgery does not affect outcomes in higher-risk patients

Modest differences in the time from diagnosis to radical prostatectomy do not appear to affect the outcomes of men with high- or very-high-risk prostate cancer, say the authors of a chart review.

image credits